321 related articles for article (PubMed ID: 33403502)
21. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.
van Berkel A; Rao JU; Kusters B; Demir T; Visser E; Mensenkamp AR; van der Laak JA; Oosterwijk E; Lenders JW; Sweep FC; Wevers RA; Hermus AR; Langenhuijsen JF; Kunst DP; Pacak K; Gotthardt M; Timmers HJ
J Nucl Med; 2014 Aug; 55(8):1253-9. PubMed ID: 24925884
[TBL] [Abstract][Full Text] [Related]
22. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.
Garcia-Carbonero R; Matute Teresa F; Mercader-Cidoncha E; Mitjavila-Casanovas M; Robledo M; Tena I; Alvarez-Escola C; Arístegui M; Bella-Cueto MR; Ferrer-Albiach C; Hanzu FA
Clin Transl Oncol; 2021 Oct; 23(10):1995-2019. PubMed ID: 33959901
[TBL] [Abstract][Full Text] [Related]
23. Metastatic pheochromocytoma and paraganglioma.
Angelousi A; Kassi E; Zografos G; Kaltsas G
Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
[TBL] [Abstract][Full Text] [Related]
24. Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches.
Kuo MJM; Nazari MA; Jha A; Pacak K
Front Endocrinol (Lausanne); 2022; 13():936178. PubMed ID: 35903274
[TBL] [Abstract][Full Text] [Related]
25. Superiority of
Jha A; Ling A; Millo C; Gupta G; Viana B; Lin FI; Herscovitch P; Adams KT; Taïeb D; Metwalli AR; Linehan WM; Brofferio A; Stratakis CA; Kebebew E; Lodish M; Civelek AC; Pacak K
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):787-797. PubMed ID: 29204718
[TBL] [Abstract][Full Text] [Related]
26. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.
Lenders JW; Duh QY; Eisenhofer G; Gimenez-Roqueplo AP; Grebe SK; Murad MH; Naruse M; Pacak K; Young WF;
J Clin Endocrinol Metab; 2014 Jun; 99(6):1915-42. PubMed ID: 24893135
[TBL] [Abstract][Full Text] [Related]
27. Imaging of pheochromocytoma and paraganglioma.
Brink I; Hoegerle S; Klisch J; Bley TA
Fam Cancer; 2005; 4(1):61-8. PubMed ID: 15883712
[TBL] [Abstract][Full Text] [Related]
28. Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management.
Hamidi O
Curr Opin Endocrinol Diabetes Obes; 2019 Jun; 26(3):146-154. PubMed ID: 30893083
[TBL] [Abstract][Full Text] [Related]
29. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach.
Andersen KF; Altaf R; Krarup-Hansen A; Kromann-Andersen B; Horn T; Christensen NJ; Hendel HW
Cancer Treat Rev; 2011 Apr; 37(2):111-9. PubMed ID: 20675056
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in the management of pheochromocytoma and paraganglioma.
Tanabe A; Naruse M
Hypertens Res; 2020 Nov; 43(11):1141-1151. PubMed ID: 32778780
[TBL] [Abstract][Full Text] [Related]
31. Metastatic Pheochromocytomas and Abdominal Paragangliomas.
Granberg D; Juhlin CC; Falhammar H
J Clin Endocrinol Metab; 2021 Apr; 106(5):e1937-e1952. PubMed ID: 33462603
[TBL] [Abstract][Full Text] [Related]
32. Paragangliomas and Pheochromocytomas: Positron Emission Tomography/Computed Tomography Diagnosis and Therapy.
Marcus C; Subramaniam RM
PET Clin; 2023 Apr; 18(2):233-242. PubMed ID: 36585340
[TBL] [Abstract][Full Text] [Related]
33. Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation.
Abdul Sater Z; Jha A; Hamimi A; Mandl A; Hartley IR; Gubbi S; Patel M; Gonzales M; Taïeb D; Civelek AC; Gharib AM; Auh S; O'Mara AE; Pacak K; Cypess AM
J Clin Endocrinol Metab; 2020 Apr; 105(4):1176-85. PubMed ID: 31903484
[TBL] [Abstract][Full Text] [Related]
34. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
35. Clinical Significance of Quantitative 123I-MIBG SPECT/CT Analysis of Pheochromocytoma and Paraganglioma.
Nakamoto R; Nakamoto Y; Ishimori T; Togashi K
Clin Nucl Med; 2016 Nov; 41(11):e465-e472. PubMed ID: 27607159
[TBL] [Abstract][Full Text] [Related]
36. Pheochromocytomas and Paragangliomas.
Tevosian SG; Ghayee HK
Endocrinol Metab Clin North Am; 2019 Dec; 48(4):727-750. PubMed ID: 31655773
[TBL] [Abstract][Full Text] [Related]
37. Malignant pheochromocytoma and paraganglioma: three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs.
Zukauskaite R; Hjorthgau K; Poulsen PL; Baerentzen S; Ladekarl M
Acta Oncol; 2011 Nov; 50(8):1255-9. PubMed ID: 21714698
[No Abstract] [Full Text] [Related]
38. International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes.
Pacak K; Clifton-Bligh R
Endocr Relat Cancer; 2023 May; 30(5):. PubMed ID: 36883571
[TBL] [Abstract][Full Text] [Related]
39. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
[TBL] [Abstract][Full Text] [Related]
40. The Pheochromocytoma/Paraganglioma syndrome: an overview on mechanisms, diagnosis and management.
Lima JV; Kater CE
Int Braz J Urol; 2023; 49(3):307-319. PubMed ID: 37115176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
